Promega develops new assay to test cytotoxicity levels
A new assay developed by Promega Corporation is capable of improving cytotoxicity reports from cell cultures gathered within 72 hours.
A new assay developed by Promega Corporation is capable of improving cytotoxicity reports from cell cultures gathered within 72 hours.
The analytic procedure allows for flexible kinetic analyse so as to determine the onset of cytotoxicity - the process by which a substance becomes toxic to cells.
CellTox Green Cytotoxicity Assay uses a special cyanine dye that acts as a fluorescent marker which is incapable of penetrating live cells but can create a strong binding with DNA from dead cells.
In this way, it can produce a clear signal, the strength of which is directly proportional to a substance's cytotoxicity. The dye is photostable and non-toxic to mammalian cells, offering extended application in laboratory work as a result.
Promega said: " The CellTox Green dye is easily multiplexed with luminescent or other fluorescent cell-based assays with an add-mix-measure protocol to provide more informative data per well.
"The assay reagent is also easily automated and scalable for use in 96-well to 1536-well formats. This assay is ideal for determining the cytotoxic effects of various treatments on cells in culture following long-term exposure."
Related News
-
News Understanding the Benefits and Advances of Cleanroom Technology
In an industry where precision and sterility are crucial concerns, cleanrooms play a vital role in maintaining the integrity of pharmaceutical products like drugs, vaccines, and other medical products. So, what is a cleanroom?
-
News AbbVie secures GBP£1.2 billion deal for Gilgamesh’s psychedelic programme
AbbVie has penned a significant agreement to acquire the bretisilocin programme from Gilgamesh Pharmaceuticals for up to £1.2 billion, marking a bold step in the pharmaceutical giant's quest to develop treatments for psychiatric disorders. -
News Gates Foundation commits US$2.5 billion to women’s health research
The Bill & Melinda Gates Foundation has announced a substantial US$2.5 billion commitment to accelerate research and development focused exclusively on women's health through 2030.
-
News Mid-year review: notable FDA drug approvals of 2025
As we fly past the halfway point of 2025, the pharmaceutical landscape reliably continues to evolve with innovative therapies addressing critical medical needs. The FDA has already approved 17 groundbreaking medications this year, each representin... -
News US FDA announces new priority vouchers for accelerated review times
The US FDA announced a new priority program for drug developers – the Commissioner’s National Priority Voucher (CNPV) program aims to enhance the health interests of the US by allowing drug developers to redeem a voucher, shortening th... -
News Google-backed start-up raises US$600 million to support AI drug discovery and design
London-based Isomorphic Labs, an AI-driven drug design and development start-up backed by Google’s AI research lab DeepMind, has raised US$600 million in its first external funding round by Thrive Capital. The funding will provide further power t... -
News AstraZeneca to invest US$2.5 billion in Beijing R&D centre
Amid investigations of former AstraZeneca China head Leon Wang in 2024, AstraZeneca have outlined plans to establish its sixth global strategic R&D centre in China. Their aim is to further advance life sciences in China with major research and manufact... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience.